GAL and Familial prostate cancer: Mice deficient for Gal1 shows reduced tumor growth due to hampered tumor vascularization [5] and silencing of Gal1 in experimental models of Kaposi’s sarcoma [6] and human prostate cancer [7] reduced tumor vascularization.